RGLS
Closed
Regulus Therapeutics Inc
8.16
0.00 (0.00%)
Last Update: 25 Jun 2025 16:30:00
Yesterday: 8.16
Day's Range: 8.16 - 8.16
Send
sign up or login to leave a comment!
When Written:
0.9439
Regulus Therapeutics Inc. is a biopharmaceutical company that focuses on the discovery and development of drugs that target microRNAs (miRNAs) for the treatment of various diseases. The company was founded in 2007 and is headquartered in San Diego, California.
Regulus’ lead product candidate, RGLS4326, is a potential treatment for autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder that causes the growth of cysts in the kidneys. The company has also developed a pipeline of other miRNA-targeting drugs for the treatment of liver diseases, immune disorders, and various types of cancer.
Regulus has collaborations with several pharmaceutical companies, including AstraZeneca, Sanofi, and Biogen. The company is also involved in various research partnerships with academic institutions and other organizations.
Regulus has faced some challenges in recent years, including a clinical hold on its ADPKD program in 2018 due to safety concerns, and a decline in its stock price. However, the company has continued to advance its pipeline and explore new therapeutic areas for miRNA-targeting drugs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Regulus’ lead product candidate, RGLS4326, is a potential treatment for autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder that causes the growth of cysts in the kidneys. The company has also developed a pipeline of other miRNA-targeting drugs for the treatment of liver diseases, immune disorders, and various types of cancer.
Regulus has collaborations with several pharmaceutical companies, including AstraZeneca, Sanofi, and Biogen. The company is also involved in various research partnerships with academic institutions and other organizations.
Regulus has faced some challenges in recent years, including a clinical hold on its ADPKD program in 2018 due to safety concerns, and a decline in its stock price. However, the company has continued to advance its pipeline and explore new therapeutic areas for miRNA-targeting drugs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








